Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST-a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Socinski, Mark A.; Paul, Sarah M.; Yun, Cindy; Hu, Sylvia; Shen, Vincent; Velcheti, Vamsidar; Mok, Tony S.; Gandara, David R.; Chae, Young Kwang; Schleifman, Erica; Fabrizio, David A.; Shames, David S.; Phan, See; Kim, Edward S.

authors

Publication Date

  • July 1, 2019

webpage

published in

category

volume

  • 79

issue

  • 13